SHANGHAI HILE BIO-TECHNOLOGY CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.07 CNY | +1.38% |
|
-6.27% | -24.65% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 8,153 | 8,243 | 8,121 | 9,853 | 6,324 | 7,046 |
| Enterprise Value (EV) 1 | 8,076 | 8,076 | 8,067 | 9,792 | 6,089 | 6,744 |
| P/E ratio | 382 x | 640 x | 1,261 x | 191 x | 51.7 x | 107 x |
| Yield | 0.08% | 0.05% | 0.03% | - | 0.58% | - |
| Capitalization / Revenue | 32 x | 29.7 x | 31.3 x | 28.4 x | 21.1 x | 29.3 x |
| EV / Revenue | 31.7 x | 29 x | 31.1 x | 28.2 x | 20.3 x | 28 x |
| EV / EBITDA | 182 x | 193 x | 395 x | 125 x | 107 x | 166 x |
| EV / FCF | -63.3 x | 16.7 x | -157 x | -59.9 x | 33.8 x | 23.4 x |
| FCF Yield | -1.58% | 5.97% | -0.64% | -1.67% | 2.96% | 4.27% |
| Price to Book | 7.72 x | 7.77 x | 7.67 x | 9.8 x | 5.55 x | 5.7 x |
| Nbr of stocks (in thousands) | 644,000 | 644,000 | 644,000 | 644,000 | 644,000 | 657,900 |
| Reference price 2 | 12.66 | 12.80 | 12.61 | 15.30 | 9.820 | 10.71 |
| Announcement Date | 4/27/19 | 4/29/20 | 4/23/21 | 4/28/22 | 4/27/23 | 4/29/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 254.6 | 278 | 259.1 | 347.3 | 300 | 240.7 |
| EBITDA 1 | 44.47 | 41.83 | 20.43 | 78.61 | 56.96 | 40.68 |
| EBIT 1 | -8.86 | -15.25 | -37.36 | 21.9 | 15.84 | 5.023 |
| Operating Margin | -3.48% | -5.49% | -14.42% | 6.31% | 5.28% | 2.09% |
| Earnings before Tax (EBT) 1 | -1.228 | 6.827 | -23.34 | 57.14 | 131.2 | 56.02 |
| Net income 1 | 21.3 | 12.15 | 8.927 | 53.86 | 121.6 | 62.87 |
| Net margin | 8.37% | 4.37% | 3.44% | 15.51% | 40.54% | 26.12% |
| EPS 2 | 0.0331 | 0.0200 | 0.0100 | 0.0800 | 0.1900 | 0.1000 |
| Free Cash Flow 1 | -127.7 | 482.5 | -51.54 | -163.6 | 180.3 | 287.9 |
| FCF margin | -50.15% | 173.55% | -19.89% | -47.11% | 60.11% | 119.59% |
| FCF Conversion (EBITDA) | - | 1,153.29% | - | - | 316.59% | 707.66% |
| FCF Conversion (Net income) | - | 3,970.45% | - | - | 148.29% | 457.91% |
| Dividend per Share 2 | 0.0100 | 0.006000 | 0.004200 | - | 0.0567 | - |
| Announcement Date | 4/27/19 | 4/29/20 | 4/23/21 | 4/28/22 | 4/27/23 | 4/29/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 76.7 | 168 | 53.8 | 61 | 235 | 302 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -128 | 482 | -51.5 | -164 | 180 | 288 |
| ROE (net income / shareholders' equity) | -1.31% | -2.62% | -3.29% | 4.69% | 10.6% | 4.38% |
| ROA (Net income/ Total Assets) | -0.33% | -0.55% | -1.34% | 0.75% | 0.59% | 0.2% |
| Assets 1 | -6,444 | -2,199 | -666.8 | 7,145 | 20,625 | 31,769 |
| Book Value Per Share 2 | 1.640 | 1.650 | 1.640 | 1.560 | 1.770 | 1.880 |
| Cash Flow per Share 2 | 0.0700 | 0.0800 | 0.0300 | 0.2400 | 0.2400 | 0.2200 |
| Capex 1 | 112 | 39 | 34.1 | 37.8 | 19.8 | 7.81 |
| Capex / Sales | 44.11% | 14.04% | 13.17% | 10.88% | 6.62% | 3.25% |
| Announcement Date | 4/27/19 | 4/29/20 | 4/23/21 | 4/28/22 | 4/27/23 | 4/29/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -24.65% | 725M | |
| -11.83% | 79.26B | |
| +15.37% | 8.39B | |
| +28.00% | 3.74B | |
| -1.39% | 3.27B | |
| +21.28% | 1.69B | |
| -3.25% | 1.56B | |
| -18.63% | 1.29B | |
| -1.17% | 1.28B | |
| -6.77% | 1.14B |
- Stock Market
- Equities
- 603718 Stock
- Financials Shanghai Hile Bio-Technology Co., Ltd.
